• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

CJ Bio Shifts Survival Strategy : 'From New Drug-Only Focus to Diversified Revenue Streams'

김나영 기자

steaming@fntimes.com

기사입력 : 2025-06-12 09:52 최종수정 : 2025-06-16 08:11

◇ CJ Bio Launches B2C Business ‘SMILE GUT’
◇ NGS Analysis Consulting Services Also Offered for Researchers
◇ Q1 Sales at KRW 900 Million, Operating Loss at KRW 6.6 Billion
◇ KRW 23 Billion Spent on R&D Last Year… 663% of Sales

CJ Bio R&D Center / Photo = CJ Bioscience

CJ Bio R&D Center / Photo = CJ Bioscience

[Korea Financial Times, Kim Nayoung] CJ BioScience (hereafter CJ Bio), once fully committed to new drug development, is accelerating its strategic shift towards revenue diversification. Supported by annual investments amounting to tens of billions of won from its parent company CJ CheilJedang, CJ Bio has continued research and development (R&D) of microbiome therapeutics but is now seeking alternative paths amid recent revenue declines.

According to industry sources on June 11, CJ Bio launched a customized bioinformatics (BI) consulting service for researchers utilizing microbiome data in April. This one-stop solution covers everything from sample extraction to next-generation sequencing (NGS) and bioinformatics interpretation, based on over a decade of accumulated data and BI expertise. CJ Bio explained that various options such as genome, gene expression, and metagenome analyses enable easy interpretation of complex data.

A CJ Bio representative said, “Many researchers have wanted to utilize microbiome data but lacked the necessary bioinformatics knowledge. We expect this service to provide new insights for diverse research activities”.

Since January, CJ Bio has also entered the B2C (business-to-consumer) market with the healthcare service ‘SMILE GUT,’ which offers personalized health information based on individual gut microbiome data. Users can check their health index (GMI) and personal gut types without visiting a hospital. This service is based on CJ Bio’s accumulated big data of 140,000 microbiome cases.

These new business ventures coincide with the company’s recent worsening profitability indicators. CJ Bio reported consolidated sales of KRW 900 million in Q1, a 9.1% decrease from the same period last year. Operating loss was KRW 6.6 billion, continuing the deficit trend from last year.

Annual performance was also weak. Last year, CJ Bio’s consolidated sales were KRW 3.4 billion, down 37.8% from 2023. Operating loss increased to KRW 35.6 billion from KRW 32.1 billion the previous year.

R&D expenses have steadily increased. Since joining the CJ Group in 2021, the company has raised research spending annually, focusing on microbiome new drug development. CJ Bio’s R&D costs rose from KRW 5.3 billion in the acquisition year to KRW 23 billion last year, amounting to 663.1% of sales.

Despite consecutive losses, CJ CheilJedang has injected capital through paid-in capital increases of KRW 24 billion and KRW 40 billion in 2023 and 2024, respectively. Thanks to group support, CJ Bio’s pre-tax loss ratio improved from 70.3% in 2022 to 32.0% in 2023 but slightly increased to 42.2% last year.

However, CJ Bio plans to actively secure direct sales revenue from new drugs starting this year. The company aims to finalize two technology licensing deals this year, led by the microbiome immuno-oncology drug ‘CJRB-101’ developed since 2023. On May 30, CJ Bio presented interim analysis results of CJRB-101’s Phase 1/2 clinical trial at the American Society of Clinical Oncology (ASCO) in Chicago.

A CJ Bio representative stated, “Our mid- to long-term business model focuses on technology transfer and exports to major domestic and international pharmaceutical or bio companies. Amid this year’s uncertain domestic and global environment, we will seize opportunities to secure a competitive edge and strive to become a global leader in microbiome innovation”.

Kim Nayoung, Korea Finacial Times (steaming@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

기자의 기사 더보기 전체보기

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 LS Cable & System Unit Gaon Cable Turns Exporter as AI Boom Lifts Nine-Month Sales Abroad Past Last Year’s Total Editor’s Note: As investment in artificial intelligence (AI) data centers and power grids grows, the wire and cable industry is drawing attention. LS Cable & System is strengthening the competitiveness of its subsidiaries and accelerating its push into global markets. Gaon Cable is transforming itself into an export-driven company, centered on the North American market, while its U.S. production unit LSCUS is expanding on the back of power demand from AI data centers. LS Marine Solution and LS Eco Energy are also securing new growth engines through submarine cables and operations in Vietn 2 Hanwha Solutions’ Pretax Profit Owes to Asset Sale, Not Core Business Hanwha Solutions’ third-quarter pretax profit turned positive, but the driver was not its core business. It was a single asset sale. The company sold intangible assets with a book value of KRW 12.5 billion and booked a gain of KRW 199.7 billion. Without that gain, this year’s third quarter would show a pretax loss of KRW 176.3 billion.The proceeds from the disposal differ by only KRW 0.8 billion from the amount of fixed assets Hanwha Solutions sold to TransGrid Energy, a Hanwha Group affiliate, over the same period. TransGrid Energy is a subsidiary of a joint venture in which Hanwha Solution 3 Lotte Chemical Pays Down JV Debt With KRW 600 Billion as Its Own Loans Get a Three-Year Reprieve Lotte Chemical contributed KRW 600 billion to help its joint venture H&L Advanced repay existing borrowings. But it has also taken on an impairment loss on its JV shares and faces additional funding support obligations. The value of the shares recognized in the merger-date accounting was less than half the per-share value assessed by an external valuation firm when the merger ratio was set. While pouring large sums into improving the JV’s finances, Lotte Chemical itself has agreed with its creditors to a three-year deferral of repayment on its covenant debt.According to the Financial Supe
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[카드뉴스] 서울에서 떠나는 6000년 시간여행, 강동선사문화축제
[카드뉴스] 강감찬을 만나는 가을, 낙성대로!
[카드뉴스] 새우젓 따라 만나는 옛 마포나루
[카드뉴스] 성북동 언덕길, 만해의 집을 만나다
[카드뉴스] 약재 향 따라 걷는 서울약령시

FT도서

더보기